Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News & insights
Blog Post: 23 JULY 2021
Roche Diabetes Care Succeeds in UK Medtech Patent Dispute Against Insulet
In the latest UK medical technology (Medtech) patent decision Insulet v Roche Diabetes Care [2021] EWHC 1933 (Pat), Ms Pat Treacy (sitting as a judge of the High Court) held that (i) Roche Diabetes…
Read more
News: 22 JULY 2021
Sapna W. Palla joins Allen & Overy’s U.S. intellectual property litigation practice
Allen & Overy today announced that Sapna W. Palla has joined the firm as a partner in its intellectual property litigation practice, based in New York. Sapna joins from Wiggin & Dana LLP, where she…
Read more
News: 27 MAY 2021
A&O advises Exscientia on its AI-driven drug discovery collaboration with Bristol Myers Squibb
Allen & Overy has advised Exscientia on its USD 1.2 billion multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb (BMS).
Read more
Publications: 15 DECEMBER 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Read moreDownload our sector brochure
